tx 3301 has been researched along with omeprazole in 1 studies
| Studies (tx 3301) | Trials (tx 3301) | Recent Studies (post-2010) (tx 3301) | Studies (omeprazole) | Trials (omeprazole) | Recent Studies (post-2010) (omeprazole) |
|---|---|---|---|---|---|
| 69 | 15 | 16 | 9,085 | 2,737 | 1,487 |
| Protein | Taxonomy | tx 3301 (IC50) | omeprazole (IC50) |
|---|---|---|---|
| Mcl-1 | Homo sapiens (human) | 3.1448 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.28 | |
| Potassium-transporting ATPase alpha chain 1 | Homo sapiens (human) | 1.45 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 2.315 | |
| Potassium-transporting ATPase subunit beta | Homo sapiens (human) | 1.45 | |
| WD repeat-containing protein 5 | Homo sapiens (human) | 1.7 | |
| Glutathione S-transferase omega-1 | Homo sapiens (human) | 4.6 | |
| Histone-lysine N-methyltransferase 2A | Homo sapiens (human) | 1.7 | |
| Muscarinic acetylcholine receptor | Cavia porcellus (domestic guinea pig) | 3.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brickl, R; Ehrlich, J; Eisert, W; Offman, E; Schobelock, MJ; VanderMaelen, CP | 1 |
1 trial(s) available for tx 3301 and omeprazole
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.
Topics: Adolescent; Adult; Aspirin; Aspirin, Dipyridamole Drug Combination; Cross-Over Studies; Dipyridamole; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Omeprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Young Adult | 2013 |